Biological Function of the Free β-Subunit: Expression and Treatment Target in Cancer. Expression and Treatment Target in Cancer.

Human Chorionic Gonadotropin (hCG)

Volumn , Issue , 2010, Pages 149-167

  Butler, Stephen A ^a   Iles, Ray K ^a  

^a MIDDLESEX UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882464496     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384907-6.00014-1     Document Type: Chapter

References (125)

1. Djewitzi W über einen fall von chorionepithelioma der harnblase. Virchows Arch 1904, 178:451-464.
2. Aschheim S, Zondek B Das hormon des hypophysenvorderlappens: testobjekt zum nachweis des hormons. Klin Wochenschr 1927, 6:248-252.
3. McFadzean AJS Feminization associated with carcinoma of the adrenal cortex. Lancet 1946, 2:940-943.
4. Iles RK, Chard T Human chorionic gonadotropin expression by bladder cancers: biological and clinical potential. J Urol 1991, 145:453-458.
5. Iles RK, Lee CL, Oliver RTD, Chard T Composition of intact hormone and free subunits in the hCG-like material found in serum and urine of patients with carcinoma of the bladder. Clin Endocrinol 1990, 32:355-364.
6. Stenman UH, Alfthan H, Hotakainen K Human chorionic gonadotropin in cancer. Clin Biochem 2004, 37:549-561.
7. Iles RK, Chard T Immunochemical analysis of human chorionic gonadotropin-like material secreted by "normal" and neoplastic urothelial cells. J Mol Endocrinol 1989, 2:107-112.
8. Iles RK, Purkis PE, Whitehead PC, Oliver RTD, Leigh I, Chard T Expression of β human chorionic gonadotropin by non-trophoblastic nonendocrine "normal" and malignant epithelial cells. Br J Cancer 1990, 61:663-666.
9. Iles RK, Butler SA Human urothelial carcinomas-a typical disease of the aged: the clinical utility of human chorionic gonadotropin in patient management and future therapy. Exp Gerontol 1998, 33:379-391.
10. Dirnhofer S, Koessler P, Ensinger C, Feichtinger H, Madersbacher S, Berger P Production of trophoblastic hormones by transitional cell carcinoma of the bladder: association to tumor stage and grade. Hum Pathol 1998, 29:377-382.
11. Mora J, Gascon N, Tabernero JM, Rodriguez-Espinosa J, Gonzalez-Sastre F Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients. Br J Cancer 1996, 74:1081-1084.
12. El-Ahmady O, Halim AB, Mansour O, Salman T, El-Din AG, Walker RP Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease. Br J Cancer 1996, 73:1486-1490.
13. Pectasides D, Bafaloucos D, Antoniou F, Gogou L, Economides N, Varthalitis J, et al. AFP, β-hCG, PSA, SCC and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol 1996, 19:271-277.
14. Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P, et al. Urinary concentration of human chorionic gonadotropin and its fragments as a prognostic marker in bladder cancer. Br J Urol 1996, 77:61-69.
15. Halim A-B, El-Ahmady O, Hamza S, Aboul-Ela M, Oehr P Urinary β-hCG in benign and malignant urinary tract disease. Disease Markers 1995, 12:109-115.
16. Chang E, Lee E, Oh SJ, Kim JS, Kang C The immunoexpressions and prognostic significance of inhibin alpha and beta human chorionic gonadotropins (HCG) in breast carcinomas. Cancer Res Treat 2005, 37:241-246.
17. Bieche I, Lazar V, Nogues C, Poynard T, Giovangrandi Y, Bellet D, et al. Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma. Clin Cancer Res 1998, 4:671-676.
18. Schwarz-Roeger U, Petzoldt B, Waldschmidt R, Walker RP, Bauknecht T, Kiechle M, et al. UGP-A tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP. Anticancer Res 1997, 17:3041-3045.
19. Hoon DS, Sarantou T, Doi F, Chi DD, Kuo C, Conrad AJ, et al. Detection of metastatic breast cancer by beta-hCG polymerase chain reaction. Int J Cancer 1996, 69:369-374.
20. Agnantis NJ, Patra F, Khaldi L, Filis S Immunohistochemical expression of subunit beta HCG in breast cancer. Eur J Gynaecol Oncol 1992, 13:461-466.
21. Li D, Wen X, Ghali L, Al-Shalabi FM, Docherty SM, Purkis P, et al. hCG beta expression by cervical squamous carcinoma: in vivo histological association with tumor invasion and apoptosis. Histopathol 2008, 53:147-155.
22. Crawford RA, Iles RK, Carter PG, Caldwell CJ, Shepherd JH, Chard T The prognostic significance of beta human chorionic gonadotropin and its metabolites in women with cervical carcinoma. J Clin Pathol 1998, 51:685-688.
23. Grosssmann M, Hoermann R, Gocze PM, Ott M, Berger P, Mann K Measurement of human chorionic gonadotropin-related immunoreactivity in serum, ascites and tumor cysts of patients with gynaecologic malignancies. Eur J Clin Invest 1995, 25:867-873.
24. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C Serum hCG β, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002, 101:545-548.
25. Lundin M, Nording S, Carpelan-Holmstrom M, Louhimo J, Alfthan H, Stenman UH, et al. A comparison of serum and tissue hCGβ as prognostic markers in colorectal cancer. Anticancer Res 2000, 20:4949-4951.
26. Kido A, Mory M, Adachi Y, Yukaya H, Ishida T, Sugimachi K Immunohistochemical expression of beta-human chorionic gonadotropin in colorectal carcinoma. Surg Today 1996, 26:966-970.
27. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 1995, 6:581-587.
28. Berzal-Cantalejo F, Sabater Marco V, Alonso Hernandez S, Jimenez Pena R, Martorell Cebollada MA Syncytial giant cell component. Review of 55 renal cell carcinomas. Histol Histopathol 2004, 19:113-118.
29. Hotakainen K, Ljunberg B, Paju A, Rasmusen T, Althan H, Stenman UH The free beta subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer 2002, 86:185-189.
30. Dirnhofer S, Freund M, Rogatsch H, Krabichler S, Berger P Selective expression of trophoblastic hormones by lung carcinoma: neurendocrine tumors exclusively produce human chorionic gonadotropin β-subunit (hCGβ). Hum Pathol 2000, 31:966-972.
31. Szturmowicz M, Wiatr E, Sakowicz A, Slodkowska K, Filipecki S, Rowinska-Zakrzewska ER The role of human chorionic gonadotropin beta subunit elevation in small-cell lung cancer patients. Tumour Biol 1999, 20:99-104.
32. Slodkwoska J, Szturmowicz M, Rudzinski P, Giedronowicz D, Sakowitcz A, Androsiuk W, et al. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels. Eur J Cancer Prev 1998, 7:51-60.
33. Yokotani T, Koizumi T, Taniguchi R, Nakagawa T, Isobe T, Yoshimura M, et al. Expression of alpha and beta genes of human chorionic gonadotropin in lung cancer. Int J Cancer 1997, 16(71):539-544.
34. Boucher LD, Yoneda K The expression of trophoblastic cell markers by lung carcinomas. Hum Pathol 1995, 26:1201-1206.
35. Shah T, Srirajaskanthan R, Bhogal M, Toubanakis C, Meyer T, Noonan A, et al. α-fetoprotein and human chorionic gonadotropin-β as prognostic markers in neuroendocrine tumor patients. Br J Cancer 2008, 99:72-77.
36. Hedstrom J, Grenman R, Ramsey H, Finne P, Lundin J, Haglund C, et al. Concentration of free hCGbeta subunit in serum as a prognostic marker for squamous-cell carcinoma of the oral cavity and oropharynx. Int J Cancer 1999, 84:525-528.
37. Bhalang K, Kafrawy AH, Miles DA Immunohistochemical study of the expression of human chorionic gonadotropin-beta in oral squamous cell carcinomas. Cancer 1999, 85:757-762.
38. Vartiainen J, Lassus H, Lehtovirta P, Finne P, Alfthan H, Butzow R, et al. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma. Int J Cancer 2008, 122:2125-2129.
39. Ind T, Iles RK, Shepherd J, Chard T Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotropin as prognostic markers for epithelial ovarian cancer. Br J Obs Gyn 1997, 104:1024-1029.
40. Sheaff MT, Martin JE, Badenoch DF, Baithun SI βhCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 1996, 49:329-332.
41. Otite U, Baithun S, Chinegwundoh F, Nargund VH, Iles RK Detection of human chorionic gonadotropin-beta in serum or urine of prostate cancer patients is of no clinical significance. Tumor Biol 2006, 27:181-186.
42. Louhimo J, Alfthan H, Stenman UH, Haglund C Serum hCG b and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncol 2004, 66:126-131.
43. Louhimo J, Nordling S, Alfthan H, von Boguslawski K, Stenman UH, Haglund C Specific staining of human chorionic gonadotropin β in benign and malignant gastrointestinal tissues with monoclonal antibodies. Histopathol 2001, 38:418-424.
44. Syrigos KN, Fyssas I, Konstandoulakis MM, Harrington KJ, Papadopoulos S, Milingos N Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma. Gut 1998, 42:88-91.
45. de Bruijn HW, ten Hoor KA, Krans M, van der Zee AG Rising serum values of beta-subunit human chorionic gonadotropin (hCG) in patients with progressive vulvar carcinomas. Br J Cancer 1997, 75:1217-1218.
46. Carter PG, Iles RK, Neven P, Ind TEJ, Shepherd JH, Chard T Measurement of urinary β core fragment of human chorionic gonadotropin in women with vulvovaginal malignancy and its prognostic significance. Br J Cancer 1995, 71:350-353.
47. Hussa RO The clinical marker hCG 1987, Praeger Publishers, New York.
48. lles RK, Czepulkowski BH, Young BD, Chard T Amplification and re-arrangement of the β-human chorionic gonadotropin (β-hCG)-human LH gene cluster is not responsible for the ectopic production of β-hCG by bladder tumor cells. J Mol Endocrinol 1989, 2:113-117.
49. Bellet D, Lazar V, Bieche I, Paradis V, Giovangrandi Y, Paterlini P, et al. Malignant transformation of non-trophoblastic cells in association with the expression of chorionic gonadotropin beta genes transcribed in trophoblastic cells. Cancer Res 1997, 57:516-523.
50. Bo M, Boime I Identification of the transcriptionally active genes of the chorionic gonadotropin β gene in vivo. J Biol Chem 1992, 267:3179-3184.
51. Rull K, Laan M Expression of β-subunit of human chorionic gonadotropin genes during the normal and failed pregnancy. Hum Reprod 2005, 20:3360-3368.
52. Giovangrandi Y, Parfait B, Asheuer M, Olivi M, Lidereau R, Vidaud M, et al. Analysis of the human CGB/LHB gene cluster in breast tumors by real-time quantitative RT-PCR assays. Cancer Lett 2001, 168:93-100.
53. Lazar V, Diez SG, Laurent A, Giovangrandi Y, Radvanyi F, Chopin D, et al. Expression of human chorionic gonadotropin β subunit genes in superficial and invasive bladder carcinomas. Cancer Res 1995, 55:3735-3738.
54. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, et al. Molecular beacon reverse transcription-PCR of human chorionic gonadotropin-beta-3, -5, and -8 mRNAs has prognostic value in breast cancer. Clin Chem 2003, 49:1074-1080.
55. Braunstein GD, Vaitukaitis JL, Carbone PP, Ross GT Ectopic production of human chorionic gonadotropin by neoplasms. Ann Intern Med 1973, 78:39-45.
56. Dosogne-Geurin M, Stolarczyk A, Borkowski A Prospective study of the alpha and beta subunits of hCG in the blood of patients with various benign and malignant conditions. Eur J Cancer 1978, 14:525-532.
57. Braunstein GD hCG expression in trophoblastic and nontrophoblastic tumors. Oncodevelopmental markers: biologic, diagnostic and monitoring aspects 1983, 35. Academic Press, New York. W.H. Fishman (Ed.).
58. Rodenburg CJ, Nieuwenhuyzen-Kruseman AC, DeMaaker HA, Fieuren EJ, Van Oosterom AT Immunohistochemical localization and chromatographic characterization of human chorionic gonadotropin in a bladder carcinoma. Arch Path Lab Med 1985, 109:1046-1048.
59. Iles RK, Oliver RTD, Kitau M, Walker C, Chard T In vitro secretion of human chorionic gonadotropin by bladder tumor cells. Br J Cancer 1987, 55:623-626.
60. Iles RK, Jenkins BJ, Oliver RTD, Blandy JP, Chard T β human chorionic gonadotropin in serum and urine. A marker for metastatic urothelial cancer. Br J Urol 1989, 64:241-244.
61. Hagen C, Gilby ED, McNeilly AS, Olgaard K, Bondy PK, Rees LH Comparison of circulating glycoprotein hormones and their subunits in patients with oat cell carcinoma of the lung and uraemic patients on chronic dialysis. Acta Endocrinologica 1976, 83:26-35.
62. Kahn CR, Rosen SW, Weintraub BD, Fajans SS, Gorden P Ectopic production of chorionic gonadotropin and its subunits by islet-cell tumors. A specific marker for malignancy. N Engl J Med 1977, 297:565-569.
63. Adejuwon CA, Segal SJ Apparent chorionic gonadotropin immunoreactivity in human non-placental tissues: reduction by protease inhibitors or heat treatment. Clin Chim Acta 1984, 137:245-253.
64. Monteiro JC, Ferguson KM, McKinna JA, Greening WP, Neville AM Ectopic production of human chorionic gonadotropin-like material by breast cancer. Cancer 1984, 53:957-962.
65. Cowley G, Smith JA, Ellison M, Gusterson B Production of beta-human chorionic gonadotropin by human squamous carcinoma cell lines. Int J Cancer 1985, 35:575-579.
66. Heitz PU, von Herbay G, Kloppel G, Komminoth P, Kasper M, Hofler H, et al. The expression of subunits of human chorionic gonadotropin (hCG) by nontrophoblastic, nonendocrine, and endocrine tumors. Am J Clin Pathol 1987, 88:467-472.
67. Cole LA, Wang Y, Elliot M, Latif M, Chambers JT, Chambers SK, et al. Urinary human chorionic gonadotropin free β-subunit and core fragment: a new marker of gynecological cancers. Cancer Res 1988, 48:1356-1360.
68. Yamaguchi A, Ishida T, Nishimura G, Kumaki T, Katoh M, Kosaka T, et al. Human chorionic gonadotropin in colorectal cancer and its relationship to prognosis. Br J Cancer 1989, 60:382-384.
69. Marcillac I, Troalen F, Bidart J-M, Ghillani P, Ribrag V, Escudier B, et al. Free human chorionic gonadotropin β subunit in gonadal and nongonadal neoplasms. Cancer Res 1992, 52:3901-3907.
70. Marcillac I, Cottu P, Theodore C, Terrier-Lacombe MJ, Bellet D, Droz JP Free hCG-β subunit as tumor marker in urothelial cancer. Lancet 1993, 341:1354-1355.
71. Daja MM, Aghmesheh M, Ow KT, Rohde PR, Barrow KD, Russell PJ β-human chorionic gonadotropin in semen: a marker for early detection of prostate cancer?. Mol Urol 2000, 4:421-427.
72. Span PN, Thomas CM, Heuvel JJ, Bosch RR, Schalken JA, vd Locht L, et al. Analysis of expression of chorionic gonadotropin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. J Endocrinol 2002, 172:489-495.
73. Jiang Y, Zeng F, Xiao C, Liu J Expression of β-human chorionic gonadotropin genes in renal cell cancer and benign renal disease tissues. J Huazhong Univ Sci Technolog Med Sci 2003, 23:291-293.
74. Moutzouris G, Yannapoulos D, Barbatis C, Zaharof A, Theodorou C Is β human chorionic gonadotropin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy?. Br J Urol 1993, 72:907-909.
75. Iles RK, Chard T Molecular insights into structure and function of human chorionic gonadotropin. J Mol Endocrinol 1993, 10:217-234.
76. Vaitukaitis JL, Braunstein GD, Ross GT A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol 1972, 113:751-758.
77. Iles RK, Delves PJ, Butler SA Does hCG or hCGβ play a role in cancer cell biology?. Mol Cell Endocrinol 2010, in press.
78. Gillott DJ, lles RK, Chard T The effects of β-human chorionic gonadotropin on the in vitro growth of bladder cancer cell lines. Br J Cancer 1996, 73:323-326.
79. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988, 58:700-703.
80. Butler SA, Staite EM, Iles RK Reduction of bladder cancer cell growth in response to hCGβ CTP37 vaccinated mouse serum. Oncol Res 2003, 14:93-100.
81. Devi GR, Oldenkamp JR, London CA, Iversen PL Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 2002, 53:200-210.
82. Jankowska A, Gunderson SI, Andrusiewicz M, Burczynska B, Szczerba A, Jarmolowski A, et al. Reduction of human chorionic gonadotropin beta subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells. Mol Cancer 2008, 7:26.
83. Butler SA, Ikram MS, Mathieu S, Iles RK The increase in bladder carcinoma cell population induced by the free β subunit of human chorionic gonadotropin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer 2000, 82:1553-1556.
84. Lapthorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, et al. Crystal structure of human chorionic gonadotropin. Nature 1994, 369:455-461.
85. Wu H, Lustbader JW, Liu Y, Canfield RE, Hendrickson WA Structure of human chorionic gonadotropin at 2.6Å resolution from MAD analysis of the selenomethionyl protein. Structure 1994, 2:545-548.
86. Butler SA, Laidler P, Porter JR, Kicman AT, Chard T, Cowan DA, et al. The beta subunit of human chorionic gonadotropin exists as a homodimer. J Mol Endocrinol 1999, 22:185-192.
87. Butler SA, Iles RK Monomeric human chorionic gonadotropin beta is responsible for autocrine growth effects. Tumor Biol 2004, 25:18-23.
88. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, De Vos AM Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 1997, 94:7192-7197.
89. Herr F, Baal N, Reisinger K, Lorenz A, McKinnon T, Preissner KT, et al. HCG in the regulation of placental angiogenesis. Results of an in vitro study. Placenta 2007, S85-S93.
90. Reisinger K, Baal N, McKinnon T, Münstedt K, Zygmunt M The gonadotropins: tissue-specific angiogenic factors?. Mol Cell Endocrinol 2007, 269:65-80.
91. Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Münstedt K, Rao CV, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002, 87:5290-5296.
92. Demir R, Kayisli UA, Seval Y, Celik-Ozenci C, Korgun ET, Demir-Weusten AY, et al. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 2004, 25:560-572.
93. Arrieta O, Michel Ortega RM, Angeles-Sánchez J, Villarreal-Garza C, Avilés-Salas A, Chanona-Vilchis JG, et al. Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors. J Exp Clin Cancer Res 2009, 28:120.
94. Coombs LM, Pigott DA, Eydmann ME, Proctor AJ, Knowles MA Reduced expression of TGFβ is associated with advanced disease in transitional cell carcinoma. Br J Cancer 1993, 67:578-584.
95. Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H Transforming growth factors-β1 and β2 in serum and urine from patients with bladder carcinoma. J Urol 1996, 157:953-957.
96. Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H Expression of transforming growth factors-β1, β2 and β3 in human bladder carcinomas. Br J Cancer 1997, 75:1753-1760.
97. Fujii D Transforming growth factor β gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somatic Cell Mol Genet 1986, 12:281-288.
98. Vitt UA, Hsu SY, Hsueh AJW Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. Mol Endocrinol 2001, 15:681-694.
99. Levitsky HI, Mongomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1 transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996, 156:3858-3865.
100. Allison JP, Hurwitz AA, Leach DR Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995, 7:682-686.
101. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A Tumour antigens recognized by T lymphocytes. Annu Rev Immunol 1994, 12:337-365.
102. Maeurer MJ, Storjus WJ, Kirkwood JM, Lotze MT New treatment options for patients with melanoma: review of melanoma-derived epitope-based peptide vaccines. Melanoma Res 1996, 6:11-24.
103. Strauss HJ Mutant ras proteins and peptides: bad news for tumors. J Natl Cancer Inst 1995, 87:1820-1822.
104. Fisk B, Chesak B, Pollack MS, Wharton JT, Ioannides CG Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/Neu prot-oncogene in vitro. Cell Immunol 1994, 157:415-427.
105. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer G, et al. Antisynthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 1990, 87:4207-4211.
106. Burchell J, Taylor-Papdimitriou J, Boshell M, Gendler S, Duhig T A short sequence within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 1989, 44:691-696.
107. Renard V, Leach DR Perspectives on the development of a therapeutic HER-2 cancer vaccine. Vaccine 2007, 25S:B17-B23.
108. Delves PJ, Iles RK, Roitt IM, Lund T Designing a new generation of anti-hCG vaccines for cancer therapy. Mol Cell Endocrinol 2007, 260-262:276-281.
109. Brennan FR, Jones TD, Hamilton WDO Cowpea mosaic virus as a vaccine carrier of heterologous antigens. Mol Biotechnol 2001, 17:15-26.
110. Talwar GP, Sharma NC, Dubey SK, Salahuddin M, Das C, Ramakrishnan S, et al. Isoimmunization against human chorionic gonadotropin with conjugates of processed 3-subunit of the hormone and tetanus toxoid. Proc Nat Acad Sci USA 1976, 73:218-222.
111. Griffin PD Immunisation against hCG. Hum Reprod 1994, 9:267-272.
112. Stevens VC Progress in the development of human chorionic gonadotropin anti-fertility vaccine. Am J Reprod Immunol 1996, 35:148-155.
113. Stevens VC, Cinader B, Powell JE, Lee AC, Koh SW Preparation and formulation of a human chrionic gonadotropin antifertility vaccine: selection of adjuvant and vehicle. Am J Reprod Immunol 1981, 1:315-321.
114. Stevens VC, Chou WS, Powell JE, Lee AC, Smoot J The identification of peptide sequences of human chorionic gonadotropin containing a conformational epitope. Immunol Lett 1986, 12:11-18.
115. Triozzi PL, Stevens VC Human chorionic gonadotropin as a target for cancer vaccines. Oncol Reports 1999, 6:7-17.
116. Talwar GP Fertility regulating and immunotherapeutic vaccines reaching trials stage. Hum Reprod Update 1997, 3(4):301-310.
117. Dirnhofer S, Klieber R, De Leeuw R, Bidart JM, Merz WE, Wick G, et al. Functional and immunological relevance of the COOH-terminal extension of human chorionic gonadotropin beta: implications for the WHO birth control vaccine. FASEB J. 1993, 7:1381-1385.
118. Berger P, Sturgeon C, Bidart JM, Paus E, Gerth R, Niang M The ISOBM TD-7 workshop on hCG and related molecules. Towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives. Tumour Biol 2002, 23:1-38.
119. Talwar GP Vaccines and passive immunological approaches for the control of fertility and hormone-dependent cancers. Immunol Rev 1999, 171:173-192.
120. Porakishvili N, Chiesa MD, Chikadze N, Martensen P, Justesen J, Lund T, et al. Elimination of luteinizing hormone cross-reactive epitopes from human chorionic gonadotropin. Vaccine 2002, 20:2053-2059.
121. Stevens VC Future perspectives for vaccine development. Scand J Immunol Suppl 1992, 11:137-143.
122. Triozzi PL, Martin EW, Gouchnour D, Aldritch W Phase 1b trial of a synthetic beta human chorionic gonadotropin vaccine in patients with metastatic cancer. Ann N Y Acad Sci 1993, 630:358-359.
123. Clinical Triozzi PL immunological effects of a synthetic beta-hCG vaccine. Int J Oncol 1994, 5:1447-1453.
124. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002, 8:2044-2051.
125. Baselga J Clinical trials of Herceptin® (trastuzumab). Eur J Cancer 2001, 37:S18-S24.